Newsletter Subject

The Small biotech scaring big Pharma

From

mainstreetalerts.com

Email Address

editor@mainstreetalerts.com

Sent On

Tue, May 7, 2024 12:03 PM

Email Preheader Text

Dear Fellow Investor, On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kin

Dear Fellow Investor, On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of genetic software that can "Cut & Paste" any disease from your body. This revolutionary new kind of treatment will not just change medicine - It has the potential to eliminate genetic disease from our species. If that sounds like science fiction, consider this - - The Nobel Prize Committee is calling it "The Holy Grail of Medicine" - The Wall Street Journal reports the company is "transforming medicine." - 60 Minutes reports the company is "revolutionizing the search for new drugs." And the biggest drug companies have rushed to invest over a $1 billion in one year alone - Juno Pharma invested $700 million. Glaxo SmithKline invested $350 million. Johnson and Johnson invested $292 million. That's on top of the $120 million Bill Gates and Google Ventures already invested into this. The list goes on and on... Never before has so much money invested in a new treatment so quickly. And because of that, it's going to create more millionaires than any other single breakthrough in history. More than the internet, more than computers, more than cars. Investor's Business Daily estimates the market is worth at least $75 billion. But right now, its stock price is just a tiny fraction of that size. [Our research proves that anyone who gets in today could make like-changing gains.]( That's if the company doesn't get taken over for fast 300% gains first. [CLICK HERE to see how you can profit from this rare opportunity ]( "The Buck Stops Here," [dylan signature] 2563 cherry hill ln, Hermitage, PA 16148, United States You may [unsubscribe]( or [change your contact details]( at any time. [Powered by:](

Marketing emails from mainstreetalerts.com

View More
Sent On

26/05/2024

Sent On

26/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.